Media Coverage · April 18, 2019
Experimental antiplatelet compound for acute stroke shows promise
April 2019. An experimental compound inhibited clot formation without increased bleeding, a common side effect of current anticlotting therapies, in a phase I study.
Read next in 'Media Coverage'
- ACT017 : un fragment d’anticorps dont l’ACTion antithrombotique est prometteuse !
- Novel antiplatelet could circumvent bleeding risk for stroke patients
- Experimental antiplatelet compound for acute stroke shows promise
- New drug to prevent clots clears safety hurdle
- New blood thinner may prevent stroke, without risk for bleeding